Main Menu

Combination Therapy Clinical Trials

Open to recruitment

EPHOS-B: EPHOS-B (Effect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study - Biological Phase) is a Phase III, multicentre, three arm, randomised controlled trial.

ICCG Neocent trial: Neocent is a multi-centre randomised, parallel group, comparative phase III neo-adjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with strongly ER positive primary breast cancer in whom it is felt cytoreductive pre-operative systemic therapy is indicated.